Establishment of a clinical procedure to remove protein bound toxins from plasma
- Charité Universitätsmedizin Berlin, Medizinische Klinik IV, AG experimentelle Nephrologie und Hypertensiologie
Projektinhalt der eXcorLab GmbH:
Main task of the kidney is to remove metabolic waste products, which have to be obligatory excreted by urine. In patients with end stage renal disease this important function cannot be fulfilled by the kidney, which leads, if not treated, to acute poisoning with lethal outcome. Hemodialysis is the treatment of choice to the acute disease and serves as a bridging to find a suitable organ for transplantation. Hemodialysis is based on the principle of diffusion and filtration by suitable membrane filters. The bulk of the toxic substances accumulating in the plasma of patients with chronic renal failure is bound to proteins and thus, by their resulting molecular size, cannot be removed by dialysis. Examples for these toxins are indoxyl sulphate, p-cresyl sulphate, phenylen acetic acid, dimethyl guanosin and phenylen ethyl amine.
In the course of the project procedures shall be developed, which allow the removal of uremic toxins by improved separation from patients blood. Consecutively approaches and methods shall lead to the use of the findings gained in the development and production of hemodialysis membranes.
To ensure that our tests meet the requirements of our customers, we have established a quality system that fulfils all the requirements of DIN EN ISO/IEC 17025:2018 and ensures the implementation of our quality policy. This makes us an accredited testing and research institute in the areas mentioned. Our accreditation is valid in around 46 countries worldwide (including the EU, the USA and Japan), as a mutual recognition agreement, known as the ILAC Arrangement, applies between the laboratory accreditation bodies of these countries.
